CA3100896C - Anti-abeta antibodies and uses thereof - Google Patents

Anti-abeta antibodies and uses thereof Download PDF

Info

Publication number
CA3100896C
CA3100896C CA3100896A CA3100896A CA3100896C CA 3100896 C CA3100896 C CA 3100896C CA 3100896 A CA3100896 A CA 3100896A CA 3100896 A CA3100896 A CA 3100896A CA 3100896 C CA3100896 C CA 3100896C
Authority
CA
Canada
Prior art keywords
seq
sequence
cdr1
cdr2
cdr3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3100896A
Other languages
English (en)
French (fr)
Other versions
CA3100896A1 (en
Inventor
Chuan Shih
Feng-Shiun Shie
Tsu-An Hsu
Santai SHEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Health Research Institutes
Original Assignee
National Health Research Institutes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Health Research Institutes filed Critical National Health Research Institutes
Publication of CA3100896A1 publication Critical patent/CA3100896A1/en
Application granted granted Critical
Publication of CA3100896C publication Critical patent/CA3100896C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA3100896A 2018-05-30 2019-05-29 Anti-abeta antibodies and uses thereof Active CA3100896C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862678080P 2018-05-30 2018-05-30
US62/678,080 2018-05-30
PCT/US2019/034259 WO2019231957A1 (en) 2018-05-30 2019-05-29 Anti-abeta antibodies and uses thereof

Publications (2)

Publication Number Publication Date
CA3100896A1 CA3100896A1 (en) 2019-12-05
CA3100896C true CA3100896C (en) 2023-08-29

Family

ID=68694402

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3100896A Active CA3100896C (en) 2018-05-30 2019-05-29 Anti-abeta antibodies and uses thereof

Country Status (8)

Country Link
US (1) US11084873B2 (https=)
EP (1) EP3801618A4 (https=)
JP (1) JP7210612B2 (https=)
KR (1) KR102523019B1 (https=)
CN (1) CN112601550B (https=)
CA (1) CA3100896C (https=)
TW (1) TWI721440B (https=)
WO (1) WO2019231957A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
AU2020214796A1 (en) 2019-01-30 2021-07-29 Truebinding, Inc. Anti-Gal3 antibodies and uses thereof
WO2021242776A2 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201404801YA (en) * 2005-12-12 2014-09-26 Ac Immune Sa Monoclonal antibody
UA102368C2 (ru) * 2005-12-12 2013-07-10 Ас Иммуне С.А. СПЕЦИФИЧЕСКИЕ В ОТНОШЕНИИ β-АМИЛОИДА 1-42 МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА, КОТОРЫЕ ИМЕЮТ ТЕРАПЕВТИЧЕСКИЕ СВОЙСТВА
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
WO2009033743A1 (en) * 2007-09-13 2009-03-19 University Of Zurich Prorektorat Forschung Monoclonal amyloid beta (abeta)-specific antibody and uses thereof
WO2009063970A1 (ja) * 2007-11-14 2009-05-22 Forerunner Pharma Research Co., Ltd. 抗gpr49抗体を用いる癌の診断および治療
DK2207568T3 (en) * 2007-11-16 2017-09-18 Univ Rockefeller ANTIBODIES SPECIFIC TO THE PROTOFIBRILE FORM OF BETA AMYLOID PROTEIN
ES2624835T3 (es) * 2009-08-06 2017-07-17 Immunas Pharma, Inc. Anticuerpos que se unen específicamente a los oligómeros A beta y uso de los mismos
CN105979962A (zh) 2012-12-07 2016-09-28 比奥根国际神经科学公司 使用抗Aβ抗体减少脑淀粉样蛋白斑块的方法
US9879076B2 (en) * 2013-03-15 2018-01-30 Ramot At Tel Aviv University Ltd. Methods and compositions with immune therapy for treatment of dementia
BR112016024214B8 (pt) * 2014-04-18 2023-12-26 Univ New York State Res Found Anticorpo monoclonal parcialmente humanizado, composição farmacêutica e uso de um anticorpo monoclonal
US10772969B2 (en) * 2015-11-09 2020-09-15 The University Of British Columbia N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
DK3430397T3 (da) * 2016-03-14 2022-05-02 Biogen Int Neuroscience Gmbh Antistofafhængig cellemedieret fagocytoseassay til pålidelig måling af optagelse af aggregerede proteiner

Also Published As

Publication number Publication date
KR102523019B1 (ko) 2023-04-18
AU2019277171A1 (en) 2020-12-03
CN112601550A (zh) 2021-04-02
EP3801618A1 (en) 2021-04-14
TWI721440B (zh) 2021-03-11
JP2021525512A (ja) 2021-09-27
JP7210612B2 (ja) 2023-01-23
CA3100896A1 (en) 2019-12-05
TW202033549A (zh) 2020-09-16
US20190367593A1 (en) 2019-12-05
WO2019231957A1 (en) 2019-12-05
KR20210041535A (ko) 2021-04-15
US11084873B2 (en) 2021-08-10
EP3801618A4 (en) 2022-07-27
CN112601550B (zh) 2023-12-08

Similar Documents

Publication Publication Date Title
JP7610279B2 (ja) アルファ－シヌクレインに対する抗体およびその用途
AU2013302540B2 (en) Methods of treating a tauopathy
AU2018200413B2 (en) Therapeutic agent or prophylactic agent for dementia
JP7357834B2 (ja) アミロイドベータに対する抗体
CN110494445B (zh) 抗α-SYN抗体及其用途
CN117024583A (zh) 抗N3pGlu淀粉状蛋白β肽抗体及其用途
US20100104577A1 (en) Methods and materials related to anti-a (beta) antibodies
KR20160065981A (ko) 신경퇴행성 장애의 치료를 위한 세마포린-4d 결합 분자의 용도
CA3100896C (en) Anti-abeta antibodies and uses thereof
US12351623B2 (en) Antibody compositions targeting non-phosphorylated alpha-synuclein aggregates
US12286469B2 (en) Humanized antibodies binding to amyloid-beta (A-beta)
CN114945592A (zh) 抗-α-突触核蛋白单克隆抗体及其使用方法
EP3574020B1 (en) Antibodies to amyloid beta
JP2026503664A (ja) 抗ａベータ抗体を用いた神経障害の治療方法
WO2016092865A1 (ja) アミロイドβの２２位及び２３位のターン構造を極めて特異的に認識する抗体
HK40040248A (en) Anti-abeta antibodies and uses thereof
HK40040248B (zh) 抗-乙型淀粉样蛋白抗体及其用途
KR20260046152A (ko) 질환 관여 세포를 제거하기 위한 의약 및 항 gpNMB 항체
JP2025508682A (ja) 神経障害を治療するための組成物及び方法
HK40113703A (zh) 神经变性疾病的治疗剂
HK40017344A (en) Antibodies to amyloid beta

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220818

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250523

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250523